AI Healthcare company Presagen will be sponsoring, speaking and exhibiting at the Women’s Health Innovation Summit (WHIS), USA, which will be held in Boston in September. The summit aims to accelerate innovation, investment, research and partnerships, to improve the access and quality of healthcare for women worldwide.
Presagen’s CEO, Dr Michelle Perugini, will be speaking on a panel discussing the maturation and future of the fertility market. More specifically, Dr Perugini will be discussing how AI will play an increasingly crucial role in supporting both fertility and women’s health more generally, in the face of significant data access and bias challenges which impact women more so than men.
Women’s health data is typically sparse, disaggregated, and distributed amongst many small specialist clinics globally. Sometimes data to create vital health products for women do not exist at all, which was the case with Presagen’s up and coming AI product for egg assessment (Life Whisperer Oocytes). Additionally, the inability to access a globally diverse dataset creates bias, limiting AI applicability to women globally.
To solve these problems Presagen has developed a global decentralized cloud network, allowing medical providers and clinics to connect, collaborate and safely share data with Presagen’s team. This allows Presagen to develop highly scalable and unbiased AI healthcare products that can be used to benefit women worldwide. Medical providers are incentivized to collaborate and contribute existing or newly generated data via royalties on future sales of the product they support to develop.
With over 200 collaborating IVF clinics worldwide, Presagen has already developed multiple products for the IVF sector, under the brand Life Whisperer. Life Whisperer’s first two products assess images of embryos to determine if they are likely to be genetically normal (have the right number of chromosomes), and if they are likely to lead to a pregnancy. Life Whisperer will be launching additional products in the future to support women undergoing IVF treatment. The next product will use AI to assess female eggs, to provide women with greater certainty around egg quality during the IVF process and also if they elect to freeze their eggs for future use.
Life Whisperer is a world-leader in the application of AI in IVF. The Life Whisperer Viability and Genetics AI-based embryo assessment tools are the first to be commercialized in a series of applications that encompass the complete IVF journey. Life Whisperer aims to improve IVF success rates at every point and, as a result, reduce time-to-pregnancy, making IVF more affordable and accessible to patients globally. Life Whisperer is being used in IVF clinics around the world.
Presagen is an AI healthcare company that is changing the way clinics, patients, and medical data from around the world are connected through AI. Its platform, The Social Network for Healthcare, connects clinics and patients globally, and enables collaboration and data sharing to create scalable AI healthcare products that are affordable and accessible for all. The decentralized network democratizes the creation of AI products, promotes collaboration through incentives, and protects data privacy and ownership. With a focus on improving Women’s Health outcomes globally, Presagen’s first product, Life Whisperer, is being used by IVF clinics globally to improve pregnancy outcomes for couples struggling with fertility. With a vision of creating the largest network of clinics, patients, and medical data from around the world, Presagen is driving the future of AI Enhanced Healthcare.